Literature DB >> 30429717

Multiple disseminated keratoacanthoma-like nodules: a rare form of distant metastases to the skin.

Alina Jankowska-Konsur1, Karolina Kopeć-Pytlarz1, Zdzisław Woźniak2, Anita Hryncewicz-Gwóźdź1,3, Joanna Maj1.   

Abstract

Entities:  

Year:  2018        PMID: 30429717      PMCID: PMC6232540          DOI: 10.5114/ada.2018.77245

Source DB:  PubMed          Journal:  Postepy Dermatol Alergol        ISSN: 1642-395X            Impact factor:   1.837


× No keyword cloud information.
Cutaneous metastases are found in approximately 0.7–10.4% of internal malignancies and they may rarely be the first symptom of the underlying neoplasm [1]. Typically, cutaneous secondaries present as a single, erythematous nodule, occasionally ulcerated, however, other presentations, including erysipelas carcinomatosa, alopecia neoplastica or carcinoma en cuirasse in the course of the breast cancer, or angiomatous tumors in the course of renal carcinoma may be occasionally observed. The metastases assimilating keratoacanthomas are extremely rare [2, 3]. Herein, we present a 72-year-old man, cigarette smoker, who was referred to our department with disseminated skin tumors of unknown etiology. On admission, dome-shaped, inflamed tumors, some of them with central, keratin-filled craters, clinically mimicking keratoacanthomas were observed on the scalp, forehead, nose, neck and trunk (back and left shoulder) (Figures 1, 2). All the lesions developed rapidly during the 2-month period preceding hospitalization.
Figure 1

Keratoacanthoma-like metastatic lesions on the nose and forehead (A) and on the shoulder (B)

Figure 2

A – metastatic carcinoma: the cicumscribed nodular growth pattern. H + E, magn. 20×; B – the features of poorly differentiated carcinoma. H + E, magn. 200×; C – metastatic carcinoma: the tumor cells strongly positive for EMA, magn. 100×

Keratoacanthoma-like metastatic lesions on the nose and forehead (A) and on the shoulder (B) A – metastatic carcinoma: the cicumscribed nodular growth pattern. H + E, magn. 20×; B – the features of poorly differentiated carcinoma. H + E, magn. 200×; C – metastatic carcinoma: the tumor cells strongly positive for EMA, magn. 100× The patient had a history of prostate cancer (Gleason score 3+3) treated with radiotherapy and hormonal therapy 4 years ago, hypertension and emphysema. He also suffered from liver cirrhosis secondary to viral hepatitis B, followed by hepatocellular carcinoma treated with transcatheter arterial chemoembolization (TACE) a year ago. On admission, laboratory tests revealed leukopenia (2370/mm3), anemia (RBC 4.10 × 106/µl, HGB 13.0 g/dl), thrombocytopenia (49000/µl), elevated aspartate aminotransferase (AST) and γ-glutamyl transferase (GGT) serum levels (78 U/l and 65 U/l, respectively, and D-dimers (6.65 µg/ml). Moreover ultrasound examination of the abdomen showed multiple hyperechogenic lesions covering the liver and X-ray of the thorax showed disseminated round shadows in both middle and lower lung fields. Biopsy of the skin lesion obtained from the forehead revealed metastatic poorly differentiated carcinoma of unknown origin (Figure 2). The immunochemistry staining showed positive reaction for epithelial membrane antigen (EMA) however other markers (pan-cytokeratin, S-100, Melan A, PSA, AMCAR and CEA) were negative. The expression of Ki67 antigen was lower than 10. Mitotic activity was assessed as 2–3 mitoses per HPF (high power field). On the computed tomography (CT) scan, new liver tumors were observed and the patient was referred to the Angiosurgery Department to have TACE. During the subsequent therapeutic procedures, the patient’s condition deteriorated significantly and he died from the liver cirrhosis decompensation 3 months after the first hospitalization. Cutaneous metastases from the internal organs clinically mimicking keratoacanthomas are extremely rarely seen in the daily practice. So far, only 11 such cases have been described in the literature [4-6]. In the reported cases, typically, the lesions presented as rapidly growing, solitary, non-tender, firm, dome-shaped nodules with a central plug of keratin, located predominantly on the head (scalp, upper and lower lips, chin). The most common primary malignancy was lung cancer (3 cases), followed by laryngeal, breast, esophagus and bronchial cancer, mesothelioma, chondrosarcoma, anaplastic large cell lymphoma and malignant melanoma (single cases) [6]. In the literature there have been only three descriptions of multiple keratoacanthoma-like metastases. They were first symptom of the underlying lung cancer in the first case [7]. In the second case, the metastases of the laryngeal cancer were observed in the location of the patient’s radiation port [8]. Multiple lesions resembling generalized eruptive keratoacanthomas of Grzybowsky have been described in one case only (a patient with malignant melanoma) [9, 10]. Keratoacanthoma-like metastases were typically observed in middle-aged and elderly patients (age range: 53–79 years). They tended to appear in the course of previously diagnosed internal malignancy rather than they were the first sign of the disease (2 cases). The appearance of the lesions was a bad prognostic factor for the majority of the patients and correlated with short survival and disease progression. In the presented case, the typical keratoacanthoma-like lesions were disseminated in three body regions (head, neck and trunk) and were a sign of the advanced malignancy. Unfortunately, the performed diagnostic procedures and rapidly worsening patient’s condition did not allow to establish the primary site of malignancy. An important conclusion of the described case is the need to perform a histopathological examination in case of skin lesions resembling keratoacanthoma in a patient with a history of cancer.

Conflict of interest

The authors declare no conflict of interest.
  10 in total

1.  Keratoacanthoma-like cutaneous metastasis of lung cancer: a learning point.

Authors:  Adam Reich; Monika Kobierzycka; Zdzislaw Woźniak; Maria Cisło; Jacek C Szepietowski
Journal:  Acta Derm Venereol       Date:  2006       Impact factor: 4.437

2.  Keratoacanthoma like secondaries on the scalp.

Authors:  V Sreedevan; S Pradeep Nair; G Nanda Kumar; Lissy Skaria; Rani Mathew; Anitha Sanker
Journal:  Indian J Dermatol Venereol Leprol       Date:  2009 Sep-Oct       Impact factor: 2.545

3.  Cancers of unknown primary site: ESMO clinical recommendation for diagnosis, treatment and follow-up.

Authors:  E Briasoulis; N Pavlidis; E Felip
Journal:  Ann Oncol       Date:  2008-05       Impact factor: 32.976

Review 4.  The cutaneous manifestations of metastatic malignant melanoma.

Authors:  Kurtis B Reed; Robert H Cook-Norris; Jerry D Brewer
Journal:  Int J Dermatol       Date:  2012-03       Impact factor: 2.736

5.  Cutaneous metastases from internal carcinoma.

Authors:  I M Reingold
Journal:  Cancer       Date:  1966-02       Impact factor: 6.860

Review 6.  Clinical manifestations of cutaneous metastases: a review with special emphasis on cutaneous metastases mimicking keratoacanthoma.

Authors:  Ryan R Riahi; Philip R Cohen
Journal:  Am J Clin Dermatol       Date:  2012-04-01       Impact factor: 7.403

Review 7.  Generalized eruptive keratoacanthomas of Grzybowski.

Authors:  C Lane Anzalone; Philip R Cohen
Journal:  Int J Dermatol       Date:  2013-12-10       Impact factor: 2.736

8.  Primary cutaneous CD30 anaplastic large cell lymphoma with keratoacanthoma-like pseudocarcinomatous hyperplasia and marked eosinophilia and neutrophilia.

Authors:  Jeng-Hsien Lin; J Yu-Yun Lee
Journal:  J Cutan Pathol       Date:  2004-07       Impact factor: 1.587

Review 9.  The unknown biology of the unknown primary tumour: a literature review.

Authors:  A J van de Wouw; R L H Jansen; E J M Speel; H F P Hillen
Journal:  Ann Oncol       Date:  2003-02       Impact factor: 32.976

10.  Metastatic laryngeal carcinoma mimicking eruptive keratoacanthomas: report of keratoacanthoma-like cutaneous metastases in a radiation port.

Authors:  Dana L Ellis; Ryan R Riahi; Andrea T Murina; Philip R Cohen
Journal:  Dermatol Online J       Date:  2014-09-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.